Feature | May 11, 2010| Dave Fornell

Laser Atherectomy Allows Ease of Use in Most PAD Cases

Laser’s versatility is a key attribute, but has limitations with calcium.

The Spectranetics laser atherectomy system can be used to debulk peripheral vessels without the need for embolic protection.

Atherectomy is a key treatment option in peripheral artery disease (PAD), and several physicians Diagnostic & Invasive Cardiology recently spoke with are fans of the laser over mechanical systems in most PAD cases. They say it is easier to use and eliminates the need for an embolic protection device, but it does have limitations when treating calcified lesions.

Jack Casas, M.D., FACC, head of the endovascular peripheral program at St. Joseph’s Hospital in Parkersburg, W. Va. (formerly of Mercy General in Sacramento, Calif.), has used several atherectomy systems in both coronary and PAD lesions. He likes the Spectranetics laser atherectomy system because it’s versatile, with indications for the coronaries, PAD, vessels below the knee, and for electrophysiology device lead extraction.

No Need for Embolic Protection
“In my experience, distal embolization is rare provided one advances the catheter slowly. It is rare to see a nonreflow complication,” he explained. The laser photo-ablates and completely destroys the plaque. “It basically vaporizes the plaque, turning it into carbon dioxide and water.”

He said the 0.9 mm coronary laser advances about 1 mm per second. It only functions for 10 seconds before shutting down for five seconds. There is no time restriction set by the laser for the peripheral catheters. The system uses a saline flush to provide a shield against damaging red blood cells. The “time out” allows blood to reflow into the area before the physician makes another run.

“It is very easy [to use],” Dr. Casas said. “It is very effective, but you need a little bit of training. Just use some forward pressure and let the laser do its work.”

While it is easy to use, he finds new operators attempt to go too fast. “The biggest thing is to get these guys to go slow,” he said.

Treating PAD
Dr. Casas uses the laser in the majority of his PAD cases, especially in chronic total occlusions (CTOs) in the superficial femoral artery (SFA). “The laser has been very good for me, especially below the knee and in trifurcations,” he said.

The laser system operates over any guide wire, which is not the case with some of the other atherectomy systems. He said another advantage is you can feel the device moving as it cuts through lesions, while mechanical devices generally require an operator to watch the device on fluoroscopy. The laser catheter also tends to follow the lumen very closely, even in tortuous vessels. These factors mean fewer fluoro views of the device, which can reduce patient radiation exposure.

After debulking, Dr. Casas follows up with balloon work. Inflation pressures can be lower in lesions that are debulked, helping lessen the risk of dissection. “The compliance of the vessel is much more friendly,” he said.

However, Dr. Casas added, “By no means is it a stand-alone therapy.”

Atherectomy in Combination With Stents
Stents simply push plaque out of the way instead of removing it. Dr. Casas believes this might be one reason for the high rates of restenosis in stented leg vessels. He uses the laser to debulk the vessel before stenting.

Generally, stents are not used below the knee because it is a hostile environment to the metal tubes. However, Dr. Casas said very high restenosis rates in these vessels has driven him to try new methods to extend the benefit of treatment in some cases. He found paclitaxel-eluting coronary stents work very well at preventing restenosis. Cook Medical is developing a paclitaxel-eluting stent specifically for a PAD indication. However, Dr. Casas said clinical data will have to show clear benefits to justify the significant cost of DES in general practice.

Cutting Through Calcium
Calcified stenoses, especially calcified CTOs, can be weak areas for the laser. “It is OK with calcium, but that is really where the Rotablator works better,” Dr. Casas said.

He has used several mechanical atherectomy devices, including the Pathway Jetstream, Boston Scientific’s Rotablator, CSI’s Diamondback 360, and ev3’s Foxhollow. He likes the concept of Jetstream device, which integrates two different sizes of cutting tips with aspiration in one catheter, but it is limited to work above the knee. For work below the knee, he prefers the Diamondback.

Related Content

biomimics, 3D stent
News | Peripheral Arterial Disease (PAD)| August 28, 2015
August 28, 2015 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania and second in th
News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in
Boston Scientific, Innova vascular self-expanding stent system, FDA approval, peripheral artery disease, PAD
Technology | Stents Peripheral| August 20, 2015
Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Innova Vascular Self-...
Hansen Medical, Magellan 10 French Robotic Catheter, FDA 510(k) clearance
Technology | Robotic Systems| July 29, 2015
The Magellan 10 French Robotic Catheter from Hansen Medical is indicated for use in the peripheral vasculature.
CSI, ViperWire Advance Peripheral Guide Wire with Flex Tip, Stealth, Diamondback

Diamondback 360 Peripheral OAS image courtesy of Cardiovascular Systems Inc.

Technology | Atherectomy Devices| July 22, 2015
Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for its...
Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD
News | Stents Peripheral| July 17, 2015
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum...
Medtronic, Protege GPS self-expanding peripheral stent, FDA approval
Technology | July 16, 2015
Medtronic plc announced that its Protege GPS self-expanding peripheral stent system has received approval from the U.S...
C.R. Bard, LEVANT 2 results, Lutonix 035 DCB, drug coated balloon, PTA
Feature | Drug-Eluting Balloons| July 08, 2015
C.R. Bard Inc. announced the publication of results from the LEVANT 2 study in the June 24, 2015, online issue of The...
Lutonix DCB, CMS, reimbursement, pass-through payment, outpatient use
News | Drug-Eluting Balloons| June 11, 2015
C.R. Bard Inc. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has improved the pass-through...
Biotronik, Pulsar-18, Michael Lichtenberg, study
News | Stents Peripheral| June 10, 2015
Biotronik announced the publication of promising clinical results regarding its Pulsar-18 stent platform. Adding to the...
Overlay Init